Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa + temozolomide + bevacizumab for recurrent glioblastoma (Phase II, single-arm)
ChiCTR2500111976Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, temozolomide and bevacizumab in glioblastoma (GBM), sponsored by Shandong Cancer Hospital. Primary endpoints: Median progression-free survival, Three-month progression-free survival rate and 1 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
thiotepatemozolomidebevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2500111976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111976.